- Home
- VOR vs IFRX Comparison
VOR vs IFRX Comparison
Compare VOR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- IFRX
- Stock Information
- Founded
- VOR 2015
- IFRX 2007
- Country
- VOR United States
- IFRX Germany
- Employees
- VOR N/A
- IFRX N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- VOR Health Care
- IFRX Health Care
- Exchange
- VOR Nasdaq
- IFRX Nasdaq
- Market Cap
- VOR 161.9M
- IFRX 143.7M
- IPO Year
- VOR 2021
- IFRX 2017
- Fundamental
- Price
- VOR $1.36
- IFRX $2.39
- Analyst Decision
- VOR Strong Buy
- IFRX Strong Buy
- Analyst Count
- VOR 7
- IFRX 1
- Target Price
- VOR $11.36
- IFRX $8.00
- AVG Volume (30 Days)
- VOR 1.1M
- IFRX 174.5K
- Earning Date
- VOR 11-07-2024
- IFRX 11-08-2024
- Dividend Yield
- VOR N/A
- IFRX N/A
- EPS Growth
- VOR N/A
- IFRX N/A
- EPS
- VOR N/A
- IFRX N/A
- Revenue
- VOR N/A
- IFRX $187,930.00
- Revenue This Year
- VOR N/A
- IFRX $392.79
- Revenue Next Year
- VOR N/A
- IFRX $156.76
- P/E Ratio
- VOR N/A
- IFRX N/A
- Revenue Growth
- VOR N/A
- IFRX 177.12
- 52 Week Low
- VOR $0.63
- IFRX $1.17
- 52 Week High
- VOR $2.50
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- VOR 59.93
- IFRX 53.97
- Support Level
- VOR $1.27
- IFRX $2.16
- Resistance Level
- VOR $1.76
- IFRX $2.65
- Average True Range (ATR)
- VOR 0.18
- IFRX 0.22
- MACD
- VOR -0.01
- IFRX -0.01
- Stochastic Oscillator
- VOR 50.67
- IFRX 62.75
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.